Scarica l'app Stockscreener
3.77
1.34%
0.05
Dopo l'orario di chiusura:
3.77
Precedente Chiudi:
$3.72
Aprire:
$3.65
Volume 24 ore:
60,512
Relative Volume:
0.04
Capitalizzazione di mercato:
$20.27M
Reddito:
$15.66M
Utile/perdita netta:
$5.83M
Rapporto P/E:
-0.1578
EPS:
-23.8939
Flusso di cassa netto:
$466.20K
1 W Prestazione:
-3.58%
1M Prestazione:
-16.59%
6M Prestazione:
-46.14%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.645
$3.91
Intervallo di 1 settimana:
$3.645
$3.95
Portata 52W:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Nome
Neuphoria Therapeutics Inc
Settore
Industria
Telefono
781-439-5551
Indirizzo
100 SUMMIT DR, BURLINGTON
Confronta NEUP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.77 | 20.00M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.78 | 117.45B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.50 | 82.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.82 | 52.92B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.45 | 52.02B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 37.94B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Reiterato | Maxim Group | Buy |
| 2022-01-10 | Iniziato | Berenberg | Buy |
| 2022-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Iniziato | Evercore ISI | Outperform |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Neuphoria Therapeutics Inc Borsa (NEUP) Ultime notizie
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Weekly Recap: Why Neuphoria Therapeutics Inc. stock could outperform in 2025Insider Buying & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
What risks investors should watch in Neuphoria Therapeutics Inc. stockMarket Activity Recap & Fast Entry High Yield Stock Tips - Bölüm Sonu Canavarı
Published on: 2025-12-20 20:44:19 - Улправда
Published on: 2025-12-20 15:41:19 - Улправда
Why Neuphoria Therapeutics Inc. stock remains on watchlistsIPO Watch & Weekly Return Optimization Alerts - Улправда
How buybacks impact Neuphoria Therapeutics Inc. stock valueInsider Selling & AI Forecast Swing Trade Picks - Улправда
Will Neuphoria Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Daily Entry Point Alerts - DonanımHaber
How Neuphoria Therapeutics Inc. stock reacts to global recession fears2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Is Neuphoria Therapeutics Inc. stock positioned for digital transformationWeekly Risk Summary & Weekly Stock Breakout Alerts - DonanımHaber
Does Neuphoria Therapeutics Inc. stock trade at a discount to peersWeekly Trend Summary & Smart Investment Allocation Insights - DonanımHaber
How Neuphoria Therapeutics Inc. stock benefits from global expansionJuly 2025 Drop Watch & Accurate Buy Signal Notifications - DonanımHaber
Neuphoria Therapeutics (NEUP) details 2025 annual meeting and vote outcomes - Stock Titan
Neuphoria Therapeutics (NASDAQ:NEUP) Cut to Strong Sell at Zacks Research - Defense World
Abeona Therapeutics (NASDAQ:ABEO) and Neuphoria Therapeutics (NASDAQ:NEUP) Critical Comparison - Defense World
ISS recommends shareholders vote for Neuphoria’s board nominees By Investing.com - Investing.com Australia
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees - Yahoo Finance
Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees - marketscreener.com
ISS recommends shareholders vote for Neuphoria’s board nominees - Investing.com
Neuphoria Therapeutics (NEUP) Gains ISS Support for Director Nom - GuruFocus
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees - The Manila Times
HC Wainwright Has Lowered Expectations for Neuphoria Therapeutics (NASDAQ:NEUP) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Neuphoria Therapeutics (NEUP) Stock Analysis Report | Financials & Insights - Benzinga
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
NEUP: Analyst Lowers Price Target by 66% but Maintains 'Buy' Rat - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. stock deliver strong dividend growthIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Neuphoria Therapeutics (NEUP) Considers Strategic Alternatives A - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer - Investing.com
Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium - marketscreener.com
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium - The Manila Times
Neuphoria (NASDAQ: NEUP) to Weigh Lynx1’s Reduced $4.75 Offer in Ongoing Review - Stock Titan
Is Neuphoria Therapeutics Inc. stock near bottom after declineEarnings Risk Report & Weekly Top Stock Performers List - Newser
Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics - marketscreener.com
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders - Yahoo Finance
Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement - marketscreener.com
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program - MSN
Neuphoria Therapeutics Inc Azioni (NEUP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):